Teva Pharmaceutical Industries Ltd. logo

Teva Pharmaceutical Industries Ltd. (TEVJF)

Market Closed
17 Dec, 20:00
OTC PINK OTC PINK
$
28. 61
0
0%
$
17.85B Market Cap
- P/E Ratio
0% Div Yield
0 Volume
0 Eps
$ 28.61
Previous Close
Day Range
28.61 28.61
Year Range
13.73 28.61
Want to track TEVJF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 40 days

Summary

TEVJF closed today higher at $28.61, an increase of 0% from yesterday's close, completing a monthly increase of 10.04% or $2.61. Over the past 12 months, TEVJF stock gained 54.65%.
TEVJF pays dividends to its shareholders, with the most recent payment made on Dec 02, 2013. The next estimated payment will be in 2 Mar 2014 on Mar 02, 2014 for a total of $1.15.
The last earnings report, released on Nov 05, 2025, exceeded the consensus estimates by 0.37%. On average, the company has surpassed earnings expectations by 0.12%, based on the last three reports. The next scheduled earnings report is due on Jan 27, 2026.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on OTC PINK (USD).

TEVJF Chart

Similar

DCM Holdings Co., Ltd.
$ 8.45
0%
Li Auto Inc.
$ 9.49
0%
San-A Co., Ltd.
$ 15.78
0%
Inditex S.A. Unsponsored ADR
$ 16.01
-0.44%
Industria de Diseño Textil S.A.
$ 65.01
+1.85%

Teva Pharmaceutical Industries Ltd. (TEVJF) FAQ

What is the stock price today?

The current price is $28.61.

On which exchange is it traded?

Teva Pharmaceutical Industries Ltd. is listed on OTC PINK.

What is its stock symbol?

The ticker symbol is TEVJF.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 17.85B.

When is the next earnings date?

The next earnings report will release on Jan 27, 2026.

Has Teva Pharmaceutical Industries Ltd. ever had a stock split?

No, there has never been a stock split.

Teva Pharmaceutical Industries Ltd. Profile

Specialty Retail Industry
Consumer Discretionary Sector
Mr. Richard D. Francis CEO
OTC PINK Exchange
IL0006290147 ISIN
IL Country
37,000 Employees
11 Nov 2010 Last Dividend
11 Dec 2002 Last Split
- IPO Date

Overview

Teva Pharmaceutical Industries Limited is a global leader in the development, manufacturing, marketing, and distribution of both generic and specialty medicines, as well as biopharmaceutical products. With operations spanning North America, Europe, Israel, and internationally, Teva focuses on providing a wide range of health solutions. The company is known for its extensive portfolio which includes various dosage forms like tablets, capsules, injectables, and more, tailored to treat a vast spectrum of conditions. Teva dedicates significant efforts to areas such as the central nervous system (CNS), respiratory, and oncology, aiming to advance healthcare and improve the quality of life for patients around the world. Established in 1901 and headquartered in Tel Aviv, Israel, Teva also engages in the production of active pharmaceutical ingredients and offers contract manufacturing services, supporting other entities in the pharmaceutical industry through an out-licensing platform.

Products and Services

  • Generic Medicines: Teva provides a comprehensive range of generic medicines, encompassing various dosage forms like tablets, injectables, and more, catering to a myriad of health conditions.
  • Specialty Medicines: The company's specialty medicine segment includes products for the treatment of conditions in CNS, respiratory diseases, and oncology. Notable offerings include:
    • BENDEKA/TREANDA: Injections used for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.
    • COPAXONE: For relapsing forms of multiple sclerosis.
    • AJOVY: Preventive treatment for migraine in adults.
    • AUSTEDO: Addresses neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia.
    • UZEDY: For the treatment of schizophrenia.
  • Biopharmaceutical Products: Includes products like GRANIX, TRISENOX, LONQUEX, and TEVAGRASTIM/RATIOGRASTIM, among others, focusing on advanced therapies.
  • Respiratory Products: A range of products designed for asthma and other respiratory conditions, including ProAir RespiClick, QVAR, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick.
  • OTC Products: Teva offers over-the-counter products under brand names such as SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA, providing accessible health solutions.
  • Active Pharmaceutical Ingredients (APIs) and Contract Manufacturing: The company provides APIs and offers contract manufacturing services, showing its versatility in the pharmaceutical industry.
  • Collaborations and Licenses: Teva has entered into collaboration agreements with companies like MedinCell, Sanofi, Alvotech, and Biolojic Design Ltd., and holds a license agreement with MODAG GmbH. These partnerships enrich its product offerings and enhance its R&D capabilities.

Contact Information

Address: 124 Dvora Hanevi’a Street
Phone: 972 3 914 8213